Press Releases
WILMINGTON, Del., Nov. 14, 2024 (GLOBE NEWSWIRE) -- The board of directors of Ashland Inc. (NYSE: ASH) has declared a quarterly cash dividend of $0.405 cents per share on the company's common stock. The dividend is payable on December 15, 2024, to stockholders of record at the close of business on
WILMINGTON, Del., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH) will host a strategy update event for analysts and investors on Tuesday, December 10, 2024, in New York City. The company will provide an in-depth review of Ashland’s strategic priorities, key initiatives and financial
Financial results for fourth-quarter fiscal 2024 1 Sales of $522 million, up one percent from the prior-year quarter Sold nutraceuticals business to Turnspire Capital Partners LLC Previously announced carboxymethylcellulose (CMC), methylcellulose (MC) and nutraceuticals portfolio optimization
Wilmington, Del., October 31, 2024 – Ten years ago, Ashland pioneered epigenetic research harnessing the power of skin microRNA and plant small RNA into botanicals and peptides to deliver outstanding skin benefits. Today Ashland is in good company with Victor Ambros and Gary Ruvkun, two American
WILMINGTON, Del., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH) today announced plans to issue its fourth-quarter fiscal 2024 earnings release at approximately 5 p.m. ET on Wednesday, November 6, 2024. The company’s live webcast with securities analysts will include an executive
Wilmington, Del., Oct. 2, 2024 – Ashland is showcasing two new life sciences products during upcoming tradeshows, CPHI Milan, October 8-10 (booth 6D20) and AAPS PharmSci 360 in Salt Lake City, UT, October 20-23 (booth 1903).
Technology successfully validated by field trials and successful customer pilots; commercial samples and material now available Wilmington, Del., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Ashland has accelerated the application of the company’s new super wetting technology platform announced last
WILMINGTON, Del., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH) today announced it has completed the sale of its nutraceuticals business to an affiliate of Turnspire Capital Partners LLC (“Turnspire”) effective August 30, 2024. The sale includes custom formulation and contract
WILMINGTON, Del., August 20, 2024 – Ashland Rad-Sure ™ blood irradiation indicators have been approved by the Association for Advancement of Blood and Biotherapies (AABB) Standards-Compliant Product Program designed to offer assurance that blood community products conform to AABB standards.
Planned ribbon cutting event demonstrates company commitment to investment in innovation platforms and local presence Wilmington, Del., Aug. 12, 2024 - Ashland has completed the second expansion of its pharmaceutical injectables manufacturing and R&D lab at the National Science Park in Mullingar,